 |
|
|
|
|
|
|
LAE-32
|
|
| LAE-32
|
| Systematic (IUPAC) name
|
6aR,9R)-N-ethyl-7-methyl-4,6,6a,7,8,9-
hexahydroindolo-[4,3-fg]quinoline-9-carboxamide
|
| Identifiers
|
| CAS number
| 478-99-9
|
| ATC code
| ?
|
| PubChem
| ?
|
| Chemical data
|
| Formula | C18H21N3O
|
| Mol. mass | 295.378 g/mol
|
| Synonyms
| LAE, Lysergic acid ethylamide, d-lysergic acid ethylamide, d-ethyllysergamide,
|
| Pharmacokinetic data
|
| Bioavailability | ?
|
| Metabolism | hepatic
|
| Half life | ?
|
| Excretion | renal
|
| Therapeutic considerations
|
| Pregnancy cat.
|
?
|
| Legal status
|
|
| Routes
| Oral
|
D-Lysergic Acid Ethylamide, (LAE-32) is a derivative of ergine. It is reported to have some LSD-like effects but is weaker and shorter lasting, with an active dose reported to be between 0.5 and 1.5 milligrams.
|
| |
|
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "LAE-32". A list of authors is available in Wikipedia.
|
|
|
|
|
|
Top